Based on findings from a randomized controlled trial in Thailand, the Centers for Disease Control and Prevention (CDC) has recommended oral medication as pre-exposure prophylaxis (PrEP) to prevent HIV infection among injecting drug users.
The CDC recommends that injecting drug users take a daily fixed-dose combination of 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine, which is marketed as Truvada. The US Food and Drug Administration last year approved an indication for Truvada to prevent HIV infection among men who have sex with men and heterosexually active men and women. The drug is used with other anti-HIV medications to treat HIV infection in teens and adults.
CDC Recommends Oral Medication to Prevent HIV in Injecting Drug Users. JAMA. 2013;310(5):471. doi:10.1001/jama.2013.16974
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: